Amgen Research (munich) Gmbh

Amgen Inc.

Amgen Research Gmbh

Pamela Bogner

Peter Kufer

Tobias Raum

Patrick Hoffmann

Andreas Wolf

Benno Rattel

Cornelius Pompe

Johannes Brozy

Matthias Friedrich

Markus Münz

Doris Rau

Markus Muenz

Elisabeth Nahrwold

Christoph Dahlhoff

Jochen Pendzialek

Ines Herrmann

Julie Bailis

Jonas Anlahr

Franziska Bott

Claudia Bluemel

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and theCD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

PSMA and CD3 bispecific T cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or theCD3&#x3b5; chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

Bispecific T cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or theCD3&#x3b5; chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

BCMA and CD3 bispecific T cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and theCD3&#x3b5; chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

Growing community of inventors

Munich, Germany

Pamela Bogner